PD39-04 ASSOCIATION OF URINE CHEMOKINES WITH CLINICAL ATTRIBUTES OF BPH/LUTS PATIENTS

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology and Natural History1 Apr 2015PD39-04 ASSOCIATION OF URINE CHEMOKINES WITH CLINICAL ATTRIBUTES OF BPH/LUTS PATIENTS Pradeep Tyagi, Jay H. Fowke, Saundra Motley, Mahendra Kashyap, Subrata Pore, Zhou Wang, and Naoki Yoshimura Pradeep TyagiPradeep Tyagi More articles by this author , Jay H. FowkeJay H. Fowke More articles by this author , Saundra MotleySaundra Motley More articles by this author , Mahendra KashyapMahendra Kashyap More articles by this author , Subrata PoreSubrata Pore More articles by this author , Zhou WangZhou Wang More articles by this author , and Naoki YoshimuraNaoki Yoshimura More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2399AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Role of inflammation is considered in the BPH and associated lower urinary tract symptoms (BPH/LUTS. Chemokines are well recognized as critical mediators of inflammatory response and previous studies have reported association of chemokines measured in prostate tissue and expressed prostatic secretions (EPS) with BPH symptoms. Here, we investigated the association of chemokines in normally voided urine of patients with International Prostate Symptom Score (IPSS)and obesity measures. METHODS We randomly selected preserved spot urine specimens obtained from 30 eligible BPH patients of Nashville Men's Health Study, who were biopsy -ve for cancer, or other suspicious findings. Prostate volume, smoking status, anthropometric measures and other lifestyle practices were also assessed. Specimens were thawed prior to analysis for CXC chemokines (CXCL-1, CXCL-8, CXCL-10), CC chemokines (CCL2 and CCL3), sIL-1ra using Luminex™ xMAP® technology and ELISA for NGF. Selected 30 patients were blocked on three prostate volume categories (<40, 40–<60, 60 cc or more) and LUTS severity (0-7, 8-35) categories, such that there were 5 participants within each prostate volume x LUTS cell. RESULTS Raw levels of CCL2 were several folds higher compared to other 6 proteins, of which CCL3 was only detectable in 7 BPH patients. Overall, transformed chemokine levels in urine were not significantly associated with prostatic enlargement or IPSS, except for mild association of CXCL-8 levels with IPSS including obstructive and irritative symptoms. Table lists respective regression coefficients (β) and significance (p) values for each chemokine and outcome measures. CXCL-8 (IL-8) and sIL-1ra also showed association with body mass index (BMI) and waist circumference of patients. CONCLUSIONS Reported association of urinary IL-8 and sIL-1ra with obesity measures and IPSS of BPH patients agrees with earlier reports on IL-8 measurment in EPS obtained from BPH patients with similar attributes. These findings support normally voided urine as a suitable matrix for identifying markers to phenotype BPH/LUTS patients in a larger sample size. Relatively higher urine levels of CCL2 may be related to its dominant contribution by bladder and prostate stroma. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e831 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Pradeep Tyagi More articles by this author Jay H. Fowke More articles by this author Saundra Motley More articles by this author Mahendra Kashyap More articles by this author Subrata Pore More articles by this author Zhou Wang More articles by this author Naoki Yoshimura More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...